TriSalus Life Sciences, Inc. Warrant financials
$0.8099+1.24%
Close Sep 24, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 |
|---|---|---|---|
| Revenue | $45.2M | $29.4M | $18.5M |
| Gross profit | $38.2M | $25.3M | $15.9M |
| Gross margin | 84.6% | 86.1% | 85.9% |
| Operating income | -$26.9M | -$36.2M | -$54.5M |
| Net income | -$69.7M | -$33.2M | -$63.6M |
| Net margin | −154.3% | −112.9% | −343.6% |
| Diluted EPS | $-1.84 | $-1.31 | $-6.77 |
| EBITDA | -$26.3M | -$35.4M | -$53.7M |
| Operating cash flow | -$18.0M | -$40.8M | -$50.6M |
| Free cash flow | -$18.9M | -$41.2M | -$51.2M |
| Diluted shares | 37.9M | 25.3M | 9.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|
| Cash & equivalents | $20.4M | $8.5M | $11.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 |
| Total debt | $33.0M | $22.1M | $0.00 |
| Total assets | $35.3M | $24.0M | $24.6M |
| Total liabilities | $69.2M | $49.9M | $51.7M |
| Shareholders' equity | -$33.9M | -$25.9M | -$27.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology